Prognostic factors and survival in Japanese patients with brain metastasis from renal cell cancer.
Brain metastasis
Graded Prognostic Assessment Score
Prognosis
Renal cell carcinoma
Sarcomatoid component
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
28
12
2018
accepted:
20
05
2019
pubmed:
28
5
2019
medline:
19
11
2019
entrez:
29
5
2019
Statut:
ppublish
Résumé
Patients with brain metastasis from renal cell carcinoma have poor outcomes despite recent advances in diagnosis and treatment. Moreover, factors affecting such poor outcomes are unclear. This study aimed to evaluate the prognostic factors associated with overall survival in renal cell carcinoma patients with brain metastasis. We retrospectively reviewed the data of 50 consecutive patients with brain metastasis from renal cell carcinoma at our institution between 1988 and 2017. The evaluated prognostic factors for overall survival included clinicopathological factors at diagnosis, treatment for brain metastasis, and the Graded Prognostic Assessment score of renal cell carcinoma. The associations between preoperative clinicopathological factors and overall survival were assessed using the log-rank test and Cox proportional hazards models for univariate and multivariate analyses, respectively. Forty-five patients were included, among whom 39 died during follow-up. The median follow-up was 8.2 months. The median survival time was 8.2 months (95% confidence interval 5.5-13.7). A Graded Prognostic Assessment score ≤ 2 (hazard ratio 1.967; 95% confidence interval 1.024-3.892; P = 0.042), the presence of sarcomatoid components (hazard ratio 3.299; 95% confidence interval 1.424-7.193; P = 0.007), and no treatment for brain metastasis (hazard ratio 2.594; 95% confidence interval 1.033-5.858; P = 0.043) were independently associated with poor prognosis in the multivariate analysis. Patients with renal cell carcinoma who develop brain metastasis have poor overall survival. The Graded Prognostic Assessment score, sarcomatoid components, and treatment for brain metastasis from renal cell carcinoma were independent factors associated with prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with brain metastasis from renal cell carcinoma have poor outcomes despite recent advances in diagnosis and treatment. Moreover, factors affecting such poor outcomes are unclear. This study aimed to evaluate the prognostic factors associated with overall survival in renal cell carcinoma patients with brain metastasis.
METHODS
METHODS
We retrospectively reviewed the data of 50 consecutive patients with brain metastasis from renal cell carcinoma at our institution between 1988 and 2017. The evaluated prognostic factors for overall survival included clinicopathological factors at diagnosis, treatment for brain metastasis, and the Graded Prognostic Assessment score of renal cell carcinoma. The associations between preoperative clinicopathological factors and overall survival were assessed using the log-rank test and Cox proportional hazards models for univariate and multivariate analyses, respectively.
RESULTS
RESULTS
Forty-five patients were included, among whom 39 died during follow-up. The median follow-up was 8.2 months. The median survival time was 8.2 months (95% confidence interval 5.5-13.7). A Graded Prognostic Assessment score ≤ 2 (hazard ratio 1.967; 95% confidence interval 1.024-3.892; P = 0.042), the presence of sarcomatoid components (hazard ratio 3.299; 95% confidence interval 1.424-7.193; P = 0.007), and no treatment for brain metastasis (hazard ratio 2.594; 95% confidence interval 1.033-5.858; P = 0.043) were independently associated with poor prognosis in the multivariate analysis.
CONCLUSIONS
CONCLUSIONS
Patients with renal cell carcinoma who develop brain metastasis have poor overall survival. The Graded Prognostic Assessment score, sarcomatoid components, and treatment for brain metastasis from renal cell carcinoma were independent factors associated with prognosis.
Identifiants
pubmed: 31134469
doi: 10.1007/s10147-019-01474-2
pii: 10.1007/s10147-019-01474-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231-1237Références
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1389-93
pubmed: 11121638
Cancer J. 2000 Nov-Dec;6(6):372-6
pubmed: 11131486
J Urol. 2002 Jan;167(1):65-70
pubmed: 11743277
J Surg Oncol. 2007 Mar 15;95(4):317-23
pubmed: 17066434
Cancer. 2008 Oct 1;113(7):1641-8
pubmed: 18671240
Urol Oncol. 2011 Jul-Aug;29(4):405-10
pubmed: 19854078
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
pubmed: 19942357
Strahlenther Onkol. 2010 Apr;186(4):210-7
pubmed: 20165820
Cancer. 2011 Feb 1;117(3):501-9
pubmed: 20862748
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
Am J Clin Oncol. 2013 Dec;36(6):620-4
pubmed: 22892430
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Clin Genitourin Cancer. 2015 Feb;13(1):59-66
pubmed: 25023939
Lancet Oncol. 2014 Nov;15(12):e549-61
pubmed: 25439697
Am J Clin Oncol. 2017 Oct;40(5):439-443
pubmed: 25730604
J Neurooncol. 2016 Oct;130(1):221-228
pubmed: 27538910
Ther Adv Med Oncol. 2016 Nov;8(6):450-459
pubmed: 27800033
Clin Genitourin Cancer. 2017 Dec;15(6):717-723
pubmed: 28552571
J Natl Compr Canc Netw. 2017 Jun;15(6):804-834
pubmed: 28596261
World Neurosurg. 2017 Dec;108:151-156
pubmed: 28754641
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Clin Oncol. 1984 Mar;2(3):169-73
pubmed: 6699668